Thaís S. Sabedot
YOU?
Author Swipe
View article: Impact of developmental state, p53 status, and interferon signaling on glioblastoma cell response to radiation and temozolomide treatment
Impact of developmental state, p53 status, and interferon signaling on glioblastoma cell response to radiation and temozolomide treatment Open
Glioblastoma (GBM) tumors exhibit extensive genomic, epigenomic, and transcriptional diversity, with significant intratumoral heterogeneity, complicating standard treatment approaches involving radiation (RT) and the DNA-alkylating agent t…
View article: Impact of genomic background and developmental state on signaling pathways and response to therapy in glioblastoma patient-derived cells
Impact of genomic background and developmental state on signaling pathways and response to therapy in glioblastoma patient-derived cells Open
Glioblastoma (GBM) tumors represents diverse genomic epigenomic, and transcriptional landscapes, with significant intratumoral heterogeneity that challenges standard of care treatments involving radiation (RT) and the DNA-alkylating agent …
View article: Table S1 from The Epigenetic Evolution of Glioma Is Determined by the <i>IDH1</i> Mutation Status and Treatment Regimen
Table S1 from The Epigenetic Evolution of Glioma Is Determined by the <i>IDH1</i> Mutation Status and Treatment Regimen Open
Table S1: GLASS surgery-level clinical and molecular characteristics (N=354)
View article: Table S5 from The Epigenetic Evolution of Glioma Is Determined by the <i>IDH1</i> Mutation Status and Treatment Regimen
Table S5 from The Epigenetic Evolution of Glioma Is Determined by the <i>IDH1</i> Mutation Status and Treatment Regimen Open
Table S5: Treatment-related probes and samples (Related to Figure 3) S5A: List of 69 IDHmut pairs with treatment information (ID of Initial and Recurrent samples and group assignment) S5B: List of differentially methylated probes associate…
View article: Table S6 from The Epigenetic Evolution of Glioma Is Determined by the <i>IDH1</i> Mutation Status and Treatment Regimen
Table S6 from The Epigenetic Evolution of Glioma Is Determined by the <i>IDH1</i> Mutation Status and Treatment Regimen Open
Table S6: Deconvolution cell proportions and probe-signature matrix S6A: Methylcibersort cell proportions S6B: Methylcibersort cell reference mixture
View article: Table S5 from The Epigenetic Evolution of Glioma Is Determined by the <i>IDH1</i> Mutation Status and Treatment Regimen
Table S5 from The Epigenetic Evolution of Glioma Is Determined by the <i>IDH1</i> Mutation Status and Treatment Regimen Open
Table S5: Treatment-related probes and samples (Related to Figure 3) S5A: List of 69 IDHmut pairs with treatment information (ID of Initial and Recurrent samples and group assignment) S5B: List of differentially methylated probes associate…
View article: Supplementary Appendix from The Epigenetic Evolution of Glioma Is Determined by the <i>IDH1</i> Mutation Status and Treatment Regimen
Supplementary Appendix from The Epigenetic Evolution of Glioma Is Determined by the <i>IDH1</i> Mutation Status and Treatment Regimen Open
List of collaborator authors
View article: Table S3 from The Epigenetic Evolution of Glioma Is Determined by the <i>IDH1</i> Mutation Status and Treatment Regimen
Table S3 from The Epigenetic Evolution of Glioma Is Determined by the <i>IDH1</i> Mutation Status and Treatment Regimen Open
Table S3A/B/C/D: Clinical summary of GLASS epigenomic samples S3A: Clinical summary of IDHmut patients who switched from GCIMP-high to GCIMP-low S3B: Clinical summary of IDHmut and IDHwt patients with known hypermutator status S3C: Clinica…
View article: Data from The Epigenetic Evolution of Glioma Is Determined by the <i>IDH1</i> Mutation Status and Treatment Regimen
Data from The Epigenetic Evolution of Glioma Is Determined by the <i>IDH1</i> Mutation Status and Treatment Regimen Open
Tumor adaptation or selection is thought to underlie therapy resistance in glioma. To investigate longitudinal epigenetic evolution of gliomas in response to therapeutic pressure, we performed an epigenomic analysis of 132 matched initial …
View article: Supplementary Appendix from The Epigenetic Evolution of Glioma Is Determined by the <i>IDH1</i> Mutation Status and Treatment Regimen
Supplementary Appendix from The Epigenetic Evolution of Glioma Is Determined by the <i>IDH1</i> Mutation Status and Treatment Regimen Open
List of collaborator authors
View article: Supplemental Figures Legends from The Epigenetic Evolution of Glioma Is Determined by the <i>IDH1</i> Mutation Status and Treatment Regimen
Supplemental Figures Legends from The Epigenetic Evolution of Glioma Is Determined by the <i>IDH1</i> Mutation Status and Treatment Regimen Open
Supplemental Figures Legends
View article: Table S4 from The Epigenetic Evolution of Glioma Is Determined by the <i>IDH1</i> Mutation Status and Treatment Regimen
Table S4 from The Epigenetic Evolution of Glioma Is Determined by the <i>IDH1</i> Mutation Status and Treatment Regimen Open
Table S4: Master regulators - list of samples and features (Related to Figure 2) S4A: List of sample profiled for ChIP-seq S4B: Results of H3K4me3 differential analysis S4C: Results of H3K27Ac differential analysis S4D: Results of gene exp…
View article: Table S6 from The Epigenetic Evolution of Glioma Is Determined by the <i>IDH1</i> Mutation Status and Treatment Regimen
Table S6 from The Epigenetic Evolution of Glioma Is Determined by the <i>IDH1</i> Mutation Status and Treatment Regimen Open
Table S6: Deconvolution cell proportions and probe-signature matrix S6A: Methylcibersort cell proportions S6B: Methylcibersort cell reference mixture
View article: Table S2 from The Epigenetic Evolution of Glioma Is Determined by the <i>IDH1</i> Mutation Status and Treatment Regimen
Table S2 from The Epigenetic Evolution of Glioma Is Determined by the <i>IDH1</i> Mutation Status and Treatment Regimen Open
Table S2: List of 132 pairs (ID of Initial and Recurrent samples)
View article: Table S4 from The Epigenetic Evolution of Glioma Is Determined by the <i>IDH1</i> Mutation Status and Treatment Regimen
Table S4 from The Epigenetic Evolution of Glioma Is Determined by the <i>IDH1</i> Mutation Status and Treatment Regimen Open
Table S4: Master regulators - list of samples and features (Related to Figure 2) S4A: List of sample profiled for ChIP-seq S4B: Results of H3K4me3 differential analysis S4C: Results of H3K27Ac differential analysis S4D: Results of gene exp…
View article: Supp Figures from The Epigenetic Evolution of Glioma Is Determined by the <i>IDH1</i> Mutation Status and Treatment Regimen
Supp Figures from The Epigenetic Evolution of Glioma Is Determined by the <i>IDH1</i> Mutation Status and Treatment Regimen Open
Supp Figures
View article: Supp Figures from The Epigenetic Evolution of Glioma Is Determined by the <i>IDH1</i> Mutation Status and Treatment Regimen
Supp Figures from The Epigenetic Evolution of Glioma Is Determined by the <i>IDH1</i> Mutation Status and Treatment Regimen Open
Supp Figures
View article: Table S3 from The Epigenetic Evolution of Glioma Is Determined by the <i>IDH1</i> Mutation Status and Treatment Regimen
Table S3 from The Epigenetic Evolution of Glioma Is Determined by the <i>IDH1</i> Mutation Status and Treatment Regimen Open
Table S3A/B/C/D: Clinical summary of GLASS epigenomic samples S3A: Clinical summary of IDHmut patients who switched from GCIMP-high to GCIMP-low S3B: Clinical summary of IDHmut and IDHwt patients with known hypermutator status S3C: Clinica…
View article: Table S2 from The Epigenetic Evolution of Glioma Is Determined by the <i>IDH1</i> Mutation Status and Treatment Regimen
Table S2 from The Epigenetic Evolution of Glioma Is Determined by the <i>IDH1</i> Mutation Status and Treatment Regimen Open
Table S2: List of 132 pairs (ID of Initial and Recurrent samples)
View article: Table S1 from The Epigenetic Evolution of Glioma Is Determined by the <i>IDH1</i> Mutation Status and Treatment Regimen
Table S1 from The Epigenetic Evolution of Glioma Is Determined by the <i>IDH1</i> Mutation Status and Treatment Regimen Open
Table S1: GLASS surgery-level clinical and molecular characteristics (N=354)
View article: Data from The Epigenetic Evolution of Glioma Is Determined by the <i>IDH1</i> Mutation Status and Treatment Regimen
Data from The Epigenetic Evolution of Glioma Is Determined by the <i>IDH1</i> Mutation Status and Treatment Regimen Open
Tumor adaptation or selection is thought to underlie therapy resistance in glioma. To investigate longitudinal epigenetic evolution of gliomas in response to therapeutic pressure, we performed an epigenomic analysis of 132 matched initial …
View article: Supplemental Figures Legends from The Epigenetic Evolution of Glioma Is Determined by the <i>IDH1</i> Mutation Status and Treatment Regimen
Supplemental Figures Legends from The Epigenetic Evolution of Glioma Is Determined by the <i>IDH1</i> Mutation Status and Treatment Regimen Open
Supplemental Figures Legends
View article: The Epigenetic Evolution of Glioma Is Determined by the <i>IDH1</i> Mutation Status and Treatment Regimen
The Epigenetic Evolution of Glioma Is Determined by the <i>IDH1</i> Mutation Status and Treatment Regimen Open
Tumor adaptation or selection is thought to underlie therapy resistance in glioma. To investigate longitudinal epigenetic evolution of gliomas in response to therapeutic pressure, we performed an epigenomic analysis of 132 matched initial …
View article: JS04.5.A HEMIZYGOUS<i>CDKN2A</i> DELETION CONFERS WORSE SURVIVAL OUTCOMES IN IDH-MUTANT GLIOMAS
JS04.5.A HEMIZYGOUS<i>CDKN2A</i> DELETION CONFERS WORSE SURVIVAL OUTCOMES IN IDH-MUTANT GLIOMAS Open
BACKGROUND The tumor suppressor gene CDKN2A is frequently deactivated in cancer. Homozygous CDKN2A deletion is a Grade 4 defining criterion for IDH-mutant gliomas. However, the prognostic value of hemizygous CDKN2A deletions is unclear. We…
View article: ODP653 DNA Methylation Markers Detected in Liquid Biopsy Specimens Differentiate Pituitary Neuroendocrine Tumors from Other Sellar and CNS Diseases
ODP653 DNA Methylation Markers Detected in Liquid Biopsy Specimens Differentiate Pituitary Neuroendocrine Tumors from Other Sellar and CNS Diseases Open
Background DNA methylation abnormalities are pervasive in pituitary neuroendocrine tumors (PitNETs). The feasibility to detect these molecular alterations in circulating cell-free DNA (cfDNA) has been reported for several central nervous s…
View article: EPCO-44. HOXD13 GENE PLAYS A ROLE AS A PUTATIVE MASTER EPIGENETIC REGULATOR IN GLIOMA RECURRENCE AND PROGRESSION
EPCO-44. HOXD13 GENE PLAYS A ROLE AS A PUTATIVE MASTER EPIGENETIC REGULATOR IN GLIOMA RECURRENCE AND PROGRESSION Open
BACKGROUND Adult diffuse glioma is a heterogenous brain tumor group that has malignant potential and recurring properties. Glioma CpG island methylator phenotype (G-CIMP) associated with chromatin remodeling encompasses two different methy…
View article: P17.12.B HOXD13 gene plays a role as a putative master epigenetic regulator in glioma recurrence and progression
P17.12.B HOXD13 gene plays a role as a putative master epigenetic regulator in glioma recurrence and progression Open
Background Adult diffuse glioma is a heterogenous brain tumor group that has malignant potential and recurring properties. Glioma CpG island methylator phenotype (G-CIMP) associated with chromatin remodeling encompasses two different methy…